Most Clicked StoriesMore >


New specialty drug division created by Pfizer

BIO SmartBrief | Feb 10, 2016

Pfizer said it will establish a new division by integrating Allergan's ophthalmology and aesthetics products to its consumer health product line upon the completion of its $160 billion purchase of Allergan. The new global specialty and consumer brand division will operate under Pfizer's innovative products unit. The acquisition is expected to be completed in the second half of this year. PMLive.com (U.K.) (02/09)


FDA concerned about surge in biosimilar workload

BIO SmartBrief | Feb 08, 2016

UCB partners with Baylor College of Medicine on neurodegenerative disease research

BIO SmartBrief | Feb 10, 2016

Astellas' $379M purchase of Ocata Therapeutics completed

BIO SmartBrief | Feb 11, 2016

Researchers around the world vow to share Zika virus data

BIO SmartBrief | Feb 12, 2016

Meda to be purchased by Mylan for $7.2B

BIO SmartBrief | Feb 11, 2016

GlaxoSmithKline to develop flu vaccines with Valneva

BIO SmartBrief | Feb 09, 2016

Developer of cancer immunotherapy gets $50M funding boost

BIO SmartBrief | Feb 11, 2016

Merck seeks FDA approval for dust mite allergy immunotherapy

BIO SmartBrief | Feb 11, 2016

Developer of cystic fibrosis drug targets $50M from IPO

BIO SmartBrief | Feb 09, 2016


Find BIO SmartBrief Issues by Date:



BIO News More >


Registration is open for the 2016 BIO Asia International Conference

BIO SmartBrief | Feb 12, 2016

Fall 2015 BIO Therapeutic Newsletters

BIO SmartBrief | Feb 12, 2016

Big savings on lab supplies, equipment & chemicals

BIO SmartBrief | Feb 11, 2016

Savings on environmental waste disposal services

BIO SmartBrief | Feb 10, 2016

Are you looking for top biotech talent? Or looking for a biotech job?

BIO SmartBrief | Feb 09, 2016




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more